Clinical Trials Update: May 15, 2006
Ulcerative Colitis Vaginal Atrophy Leukemia
(HealthDayNews) -- Here are the latest clinical trials, courtesy of CenterWatch:
This study is being conducted in the U.S. and Europe to evaluate the safety and efficacy of visilizumab for the treatment of severe ulcerative colitis (UC). Volunteers at least 18 who have been diagnosed with UC by colonoscopy or barium enema within 36 months and have an active disease despite ongoing treatment with steroids may qualify. Volunteers will participate in intensive weekly-to-monthly evaluations for one year.
Research sites are located throughout the world.
This clinical research study will evaluate an investigational medication to treat symptoms of menopause. Women 40 to 65 who have not had a hysterectomy, a period for at least six months, and have at least one moderate-to-severe vaginal symptom such as dryness, irritation, itching, or pain with sexual activity may be eligible.
The research site is in Chaska, Minn.
This study will evaluate the effectiveness of cloretazine in elderly patients with poor risk de novo AML. Volunteers must be at least 60, have had no prior chemotherapy with or without radiation, and no history of MDS, myeloproliferative disease or favorable cytogenetics. In addition, patients must meet at least one of the following criteria: unfavorable cytogenetics, ECOG 2, cardiac / pulmonary / hepatic/ organ dysfunction, or be at least 70 years or older.
The research site is in Indianapolis, Ind.
Copyright 2006 CenterWatch. All rights reserved.